4(5)-Amino-5(4)-Imidazolecarboxamide CAS 360-97-4 Assay ≥99.5% (HPLC) Temozolomide Intermediate Factory

Chemical Name: 4(5)-Amino-5(4)-Imidazolecarboxamide  CAS: 360-97-4 Assay: ≥99.5% (HPLC) Appearance: White to Similar White Crystal Powder  Intermediate of Temozolomide (CAS: 85622-93-1) High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer with High Purity and Commercial Production Supply Temozolomide and Related Intermediates: Temozolomide CAS: 85622-93-1 4(5)-Amino-5(4)-Imidazolecarboxamide CAS: 360-97-4 5(4)-Amino-4(5)-Imidazolecarboxamide Hydrochloride CAS: 72-40-2
Item Specifications
Appearance White to Similar White Crystal Powder
Assay / Analysis Method  ≥99.5% (HPLC)
Melting Point 169.0~173.0℃
Loss on Drying ≤12.5%
Heavy Metals (as Pb) ≤20ppm
Solubility Clear (5% in Water)
Individual Impurity ≤0.20%
Total Impurities ≤0.50%
Residual Solvents
Xylene ≤0.20%
Ethanol ≤0.50%
Test Standard Enterprise Standard
Usage Intermediate of Temozolomide (CAS: 85622-93-1)
Synthetic Route (CAS 360-97-4) Synthetic Route (CAS 360-97-4)

Description:

Specifications:

Package & Storage:

Chemical Name 4(5)-Amino-5(4)-Imidazolecarboxamide
Synonyms 4(5)-Aminoimidazole-5(4)-Carboxamide; 5-Amino-3H-Imidazole-4-Carboxamide; AICA
CAS Number 360-97-4
CAT Number RF-PI936
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C4H6N4O
Molecular Weight 126.12
Solubility  Soluble in DMSO, Methanol, Water 
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

4(5)-Amino-5(4)-Imidazolecarboxamide (CAS: 360-97-4) is metabolite of Temozolomide (CAS: 85622-93-1), used as an intermediate of Temozolomide. Temozolomide is the first effective orally-taken imidazole and tetrazine-class anticancer drug which belongs to the second generation of an alkylating agent with antitumor activity without liver metabolic activation after oral administration. Temozolomide was launched for the first time in the UK for the treatment of patients with glioblastoma multiforme showing recurrence or progression after standard therapy.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours